Cell engineering techniques improve pharmacology of cellular therapeutics

Liang, Kaini; Du, Yanan

doi:10.1016/j.bbiosy.2021.100016

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the environmental component of stem-cell-based therapy, especially graphene-based nanomaterials, has received significant attention for its role as a temporary extracellular matrix (ECM) for stem cell culture. Previous studies have suggested that graphene-based nanomaterials may be able to unlock the potential of stem-cell-based therapies [ 14 , 15 ]. Particularly, graphene oxide (GO) has been extensively studied for its adhesive ability and biocompatibility with MSCs to regulate the cell signaling that triggers cell responses, including cell proliferation and differentiation [ 14 , 16 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Peptide Conjugate on Multilayer Graphene Oxide Film for the Osteogenic Differentiation of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells

et al. 2021

View full text Add to dashboard Cite

Graphene oxide (GO) is extensively studied as a template material for mesenchymal stem cell application due to its two-dimensional nature and unique functionalization chemistries. Herein, a new type of peptide-conjugated multilayer graphene oxide (peptide/m-GO film) was fabricated and used as biomaterial for culturing human Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs). The characterization of the peptide/m-GO films was performed, and the biocompatibility of the WJ-MSCs on the peptide/m-GO films was investigated. The results demonstrated that the peptide conjugate on the m-GO film did not hamper the normal growth of WJ-MSCs but supported the growth of WJ-MSCs after the 6-day culture period. In addition, the osteogenic differentiation of WJ-MSCs on the peptide/m-GO films was enhanced as compared with the parent m-GO film. Therefore, such peptide-conjugated m-GO films could provide a highly biocompatible and multifunctional 2D material to tailor the potential application of WJ-MSCs in bone tissue regeneration.

show abstract

Section: Introductionmentioning

confidence: 99%

Peptide Conjugate on Multilayer Graphene Oxide Film for the Osteogenic Differentiation of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells

et al. 2021

View full text Add to dashboard Cite

show abstract

Human Health, Environmental Comfort and Well-Being. Part 1. Engineering and Design Resources of the Bioindustry on the Way to Safe Competition with the Resources of Natural Biocenoses and Health-Saving Systems

Suchkov,

Abe,

Murphy

et al. 2024

Uspehi sovremennoj biologii

View full text Add to dashboard Cite

Everyone has the right to the highest attainable standard of health, and modern preventive, preventive and rehabilitative manipulations promote health and well-being. Thanks to a number of fundamental projects on the study of human health at various levels (genomic, proteomic, and metabolomic), and molecular mechanisms of the development of pathological conditions, there has been a great leap in the field of applied sectors of industrial biotechnology, including segments of the pharmaceutical and food industries, significantly replenished health-saving resources and improved the quality of life of the population. This article will review the advanced achievements of fundamental and applied research, as well as promising areas of the bioindustry.

show abstract

Casgevy: Innovative Medicinal Products Require Innovative Approaches to Regulatory Assessment

Kerwash,

Johnston

2024

Pharmaceutics

View full text Add to dashboard Cite

Casgevy (exa-cel) is an autologous cellular therapy modified ex vivo by a CRISPR-Cas9-mediated gene-editing technology. For Casgevy to be granted the indication in transfusion-dependent β-thalassemia, one single-arm trial was submitted which was not amenable to conventional statistical analysis of ‘effect of cause’. Therefore, an analysis was conducted on the basis of ‘cause of effect’ making use of the scheme described by Toulmin coupled to an analysis of causal inference. Based on the current data within the submitted study: subjects with transfusion-dependent β-thalassemia no longer needed a red blood cell transfusion with a 93-percent probability if and only if administered Casgevy; PNS = 93%. It is acknowledged that unknown elements of safety may yet be revealed by long-term follow-up of recipients of Casgevy. Its durability of efficacy is, at present, also an unknown that may also be ascertained by long-term follow-up of recipients. The limitations of a causal analysis are related to assumptions of the proposed causal structure which may not capture the complexity of the real world. Overall, the claim that Casgevy is indicated to treat people with transfusion-dependent β-thalassemia is considered to be supported by the results of the submitted study; the benefit–risk evaluation of Casgevy is found to be positive.

show abstract

Cell engineering techniques improve pharmacology of cellular therapeutics

Cited by 3 publications

References 10 publications

Peptide Conjugate on Multilayer Graphene Oxide Film for the Osteogenic Differentiation of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells

Peptide Conjugate on Multilayer Graphene Oxide Film for the Osteogenic Differentiation of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells

Human Health, Environmental Comfort and Well-Being. Part 1. Engineering and Design Resources of the Bioindustry on the Way to Safe Competition with the Resources of Natural Biocenoses and Health-Saving Systems

Casgevy: Innovative Medicinal Products Require Innovative Approaches to Regulatory Assessment

Contact Info

Product

Resources

About